Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Other Non Operating Income (2020 - 2025)

Historic Other Non Operating Income for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to -$4.9 million.

  • Lyell Immunopharma's Other Non Operating Income fell 1120000.0% to -$4.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 million, marking a year-over-year increase of 194903.85%. This contributed to the annual value of $4.7 million for FY2024, which is 15427.95% up from last year.
  • As of Q3 2025, Lyell Immunopharma's Other Non Operating Income stood at -$4.9 million, which was down 1120000.0% from $1.2 million recorded in Q2 2025.
  • In the past 5 years, Lyell Immunopharma's Other Non Operating Income ranged from a high of $4.3 million in Q4 2024 and a low of -$4.9 million during Q3 2025
  • Moreover, its 5-year median value for Other Non Operating Income was -$14000.0 (2022), whereas its average is $310368.4.
  • In the last 5 years, Lyell Immunopharma's Other Non Operating Income soared by 676818.18% in 2022 and then plummeted by 1120000.0% in 2025.
  • Quarter analysis of 5 years shows Lyell Immunopharma's Other Non Operating Income stood at -$44000.0 in 2021, then skyrocketed by 6768.18% to $2.9 million in 2022, then crashed by 117.25% to -$506000.0 in 2023, then soared by 948.22% to $4.3 million in 2024, then crashed by 213.21% to -$4.9 million in 2025.
  • Its Other Non Operating Income stands at -$4.9 million for Q3 2025, versus $1.2 million for Q2 2025 and $1.3 million for Q1 2025.